Notice of clarification to drug manufacturers and sponsors - Risk Management Plans - Update
This notice is being issued to clarify to drug manufacturers and sponsors that elements of Risk Management Plans (RMPs) required by Health Canada, such as controlled distribution programs, are not intended to restrict access to Canadian Reference Products (CRPs) for generic drug manufacturers for the purposes of conducting comparative testing.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Notice of clarification to drug manufacturers and sponsors - Risk Management Plans - UpdateHTMLEnglish publication HTML
-
Notice of clarification to drug manufacturers and sponsors - Risk Management Plans - UpdateHTMLFrench publication HTML
Similar records